€80.0M
The financing round was led by IQ Capital to accelerate clinical trials for glioblastoma and other solid tumours.
T
Trogenix
Developer of Trojan horse cancer therapies targeting aggressive solid tumours.
Edinburgh, UK—Founded 2023
€80.0MTotal raised
Scottish biotech developer utilising synthetic biology to engineer targeted cancer treatments.
Categories
Team
KM
Ken Macnamara
Chief Executive Officer
SP
Steve Pollard
Professor